文献速递慢性肾脏病

CKD进展临床试验中GFR斜率的临床意义

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-04-15

该研究基于66项随机治疗比较,用贝叶斯荟萃回归分析急性与慢性GFR斜率对临床终点的独立影响。结果显示两者均独立预测终点,急性效应变异解释大部分终点效应差异,支持3年总斜率作为主要斜率结局。

要点

  • 急性与慢性GFR斜率变化均独立预测肾脏临床终点。
  • 急性效应独立于慢性斜率影响临床终点。
  • 支持3年总斜率作为随机试验主要斜率结局。

核心结论

  • 治疗对急性和慢性GFR斜率的影响均是临床终点的独立决定因素。
  • 急性效应的变异解释了既往试验中临床终点治疗效应的大部分变异。
  • 结果支持将3年总斜率作为随机试验的主要斜率结局。

研究设计与样本

  • 从既往CKD临床试验中纳入66项随机治疗比较。
  • 估计治疗对急性(3个月前)和慢性(3个月后)GFR斜率及肾脏衰竭或血清肌酐翻倍终点的影响。
  • 采用新型贝叶斯荟萃回归框架,在单一多变量模型中关联治疗对终点与急慢性斜率的影响。

主要发现

  • 治疗对急性和慢性斜率的影响独立预测临床终点效应,中位R2(95%可信区间)为0.95(0.79至1.00)。
  • 固定慢性斜率效应时,治疗组较对照组急性GFR下降每多1 ml/min per 1.73 m2,临床终点风险比增加11.4%(7.9%–15.0%),不利于治疗。
  • 急性和慢性斜率的最优权重与3年总斜率一致,即从基线至3年的平均斜率。

关键数值与推荐

  • 急性GFR下降每多1 ml/min per 1.73 m2,临床终点风险比增加11.4%(7.9%–15.0%)。
  • 中位R2(95%可信区间)为0.95(0.79至1.00)。

临床怎么用

  • 在CKD进展临床试验中,可考虑采用3年总斜率作为主要斜率终点。
  • 解读GFR斜率终点时需分别评估急性与慢性斜率效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Acute effects impact the clinical endpoint independently of treatment effects on the chronic slope. Our findings support the 3-year total slope as the primary slope-based outcome in randomized trials. BACKGROUND: Slope of the GFR is considered a validated surrogate endpoint for CKD trials. However, differing short-term and long-term treatment effects on GFR slope can create ambiguities concerning the appropriate period for evaluating slope, in part because current methods cannot separate the distinct contributions of the acute (before 3 months) and chronic (after 3 months) slopes for treatment effects on clinical endpoints (CEs). METHODS: We estimated treatment effects on the acute and chronic GFR slopes and on the established CE of kidney failure or serum creatinine doubling for 66 randomized treatment comparisons from previous CKD clinical trials. We used a novel Bayesian meta-regression framework to relate treatment effects on the established CE to both the acute and chronic slopes in a single multivariable model to determine the independent contributions of the acute and chronic slopes. RESULTS: Treatment effects on both the acute and chronic slopes independently predicted the treatment effect on the established CE with a high median R2 (95% credible interval) of 0.95 (0.79 to 1.00). For a fixed treatment effect on the chronic slope, each 1 ml/min per 1.73 m2 greater acute GFR decline for the treatment versus control increased the hazard ratio for the established CE by 11.4% (7.9%–15.0%), against the treatment. The optimal weights for the acute and chronic slopes were consistent with the 3-year total slope defined as the average slope extending from baseline to 3 years. CONCLUSIONS: Treatment effects on both the acute and chronic GFR slopes are independent determinants of the effects on the established CE, with variation in acute effects accounting for much of the observed variation in treatment effects on the CE across previous trials. Our results establish that acute effects affect the CE independently of treatment effects on the chronic slope and support the 3-year total slope as the primary slope-based outcome in randomized trials.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Greene T, Collier W, Haaland B, et al. Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression. Clin J Am Soc Nephrol. 2025. PMID: 40237639. doi:10.2215/CJN.0000000662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。